Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Nasopharyngeal Neoplasms, Neoplasm Metastasis, Oropharyngeal Neoplasms, Recurrence

NCT06998069 2025-12-30

Head and Neck Cancer Study Project in the Geriatric Population

Phase 3 Recruiting

20 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT01154920 2025-12-17

Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma

Phase 2 Active not recruiting

128 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT06046482 2025-10-22

Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma

Phase 2 Terminated

4 enrolled 11 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT00875849 2025-09-30

AACER

Phase 2 Completed

53 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Tongue Neoplasms

NCT06856213 2025-08-21

ERBIOTAX

Phase 2 Recruiting

65 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT00665392 2025-08-01

ECHO-07

Phase 2 Completed

42 enrolled 24 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Tongue Neoplasms

NCT06935188 2025-07-18

Dalpicilib Plus Cetuximab Compared With Cetuximab Alone in HPV-negative, Anti-PD-1-resistant R/M HNSCC

Phase 2 Recruiting

98 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04282109 2025-06-26

NIVOTAX

Phase 2 Completed

141 enrolled 40 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT07015333 2025-06-11

Case Review of Patients With Betel Nut-induced Oral Cancer Treated With Pembrolizumab and Cetuximab

Completed

31 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT03524326 2025-05-13

Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma

Phase 1 Completed

24 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT05930938 2025-05-09

XXL_2022-01

Phase 3 Terminated

19 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04278092 2025-05-08

Paclitaxel Plus Cetuximab After First-line Checkpoint Inhibitor Failure

Phase 2 Completed

57 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT02999087 2025-05-07

REACH

Phase 3 Active not recruiting

707 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT03498378 2025-04-03

Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Phase 1 Active not recruiting

24 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Neoplasms

NCT06869473 2025-03-14

AVEC-119

Phase 2 Recruiting

67 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT04091867 2025-02-24

sEphB4-HSA With RT+Chemo or Cetux in Patients With Intermediate to High Risk LAHNSCC

Phase 1 Completed

3 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT02573493 2024-12-27

APA

Phase 2 Completed

96 enrolled 34 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT06728618 2024-12-11

OSCC

Phase 2 Not yet recruiting

28 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06647563 2024-10-18

Neoadjuvant Toripalimab + Chemotherapy ± Cetuximab in Locally Advanced Head and Neck Squamous Cell Carcinoma (Neo-ICT)

Phase 3 Not yet recruiting

355 enrolled

Head & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck

NCT03422536 2024-09-04

Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma

Phase 2 Completed

78 enrolled 16 charts

Head & Neck

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Lip Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT01588431 2024-02-14

Bevacizumab/Ph 2 for Locally Advanced Head and Neck Cancer

Phase 2 Completed

3 enrolled 7 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT02101034 2023-12-21

PD 0332991 and Cetuximab in Patients With Incurable SCCHN

Phase 1/2 Completed

96 enrolled 17 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06107114 2023-11-22

CZCNRHNSCC

Phase 2 Unknown

52 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT02624128 2023-11-13

V-CHANCE

Phase 2 Unknown

39 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasm Metastasis, Recurrence

NCT06081582 2023-10-13

Toripalimab in Combined With Cetuximab，Chemotherapy for Conversion Therapy of Locally Nonresectable OCSCC

Phase 2 Unknown

33 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT05993858 2023-08-15

PC-1

Phase 2 Not yet recruiting

33 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT02707588 2023-02-28

PembroRad

Phase 2 Completed

133 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04359199 2023-02-10

QUASAR

Unknown

42 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Deglutition Disorders, Head and Neck Neoplasms, Oropharyngeal Neoplasms

NCT02764593 2022-11-29

Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer

Phase 1 Completed

40 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT02268695 2022-08-23

TPExtreme

Phase 2 Completed

541 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT01864772 2022-08-19

ELANFIT

Phase 2 Completed

85 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Recurrence

NCT01884259 2022-05-26

HNO-2

Phase 2 Completed

100 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Laryngeal Diseases

NCT04672772 2022-03-23

Cetuximab Plus Paclitaxel as First Line for Recurrent and/or Metastatic SCCHN: Real World Data.

Completed

531 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT01104922 2022-02-14

Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck

Phase 2 Completed

48 enrolled 15 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT02438995 2021-11-03

Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck

Phase 1 Terminated

11 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

Clinical Trials

Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC

Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCC

Study Evaluating [18F]NOTA-ABY030 for Safety and Tolerability of Indeterminate Primary and/or Metastatic Disease in Head and Neck Squamous Cell Carcinoma

CACTUX

Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin

Pilot Study of Imatinib Cetuximab Combo for H & N Cancer

Los Tres Paso: Neoadjuvant Palbociclib Monotherapy, Concurrent Chemoradiation Therapy, Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma

Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer

Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer

CIML NK Cell in Head & Neck Cancer

PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC

Camrelizumab Combined With EGFR Monoclonal Antibody or Chemotherapy for Perioperative Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma

A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)

Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

Head and Neck Cancer Study Project in the Geriatric Population

Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma

Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma

AACER

ERBIOTAX

ECHO-07

Dalpicilib Plus Cetuximab Compared With Cetuximab Alone in HPV-negative, Anti-PD-1-resistant R/M HNSCC

NIVOTAX

Case Review of Patients With Betel Nut-induced Oral Cancer Treated With Pembrolizumab and Cetuximab

Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma

XXL_2022-01

Paclitaxel Plus Cetuximab After First-line Checkpoint Inhibitor Failure

REACH

Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

AVEC-119

sEphB4-HSA With RT+Chemo or Cetux in Patients With Intermediate to High Risk LAHNSCC

APA

OSCC

Neoadjuvant Toripalimab + Chemotherapy ± Cetuximab in Locally Advanced Head and Neck Squamous Cell Carcinoma (Neo-ICT)

Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma

Bevacizumab/Ph 2 for Locally Advanced Head and Neck Cancer

PD 0332991 and Cetuximab in Patients With Incurable SCCHN

CZCNRHNSCC

V-CHANCE

Toripalimab in Combined With Cetuximab，Chemotherapy for Conversion Therapy of Locally Nonresectable OCSCC

PC-1

PembroRad

QUASAR

Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer

TPExtreme

ELANFIT

HNO-2

Cetuximab Plus Paclitaxel as First Line for Recurrent and/or Metastatic SCCHN: Real World Data.

Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck

Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck